SCHEMBL22443463

SCHEMBL22443463

CC1(C)CC[C@H]([C@H](O)c2cccc(F)c2)N1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 1/20 0.39
▸ OPRK1 P41145 3/20 0.39
▸ OPRM1 P35372 2/20 0.39
▸ OPRD1 P41143 2/20 0.39
▸ OPRL1 P41146 2/20 0.39
▸ SIGMAR1 Q99720 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ CCR5 P51681 1/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ AMPD2 Q01433 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22443642 1.00 GRIN2B (0.39) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443639 1.00 GRIN2B (0.39) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443465 1.00 GRIN2B (0.39) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443467 1.00 GRIN2B (0.39) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443616 0.93 GRIN2B (0.38) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443614 0.93 GRIN2B (0.38) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443437 0.93 GRIN2B (0.38) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443439 0.93 GRIN2B (0.38) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443442 0.93 GRIN2B (0.38) GRIN2BOPRK1OPRM1OPRD1OPRL1
SCHEMBL22443486 0.84 GRIN2B (0.40) GRIN2BOPRK1OPRM1OPRD1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 — — US disclosed
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 — — US disclosed
EP-3941468-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 — — EP disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA GPR119, SLC5A1, SLC5A2 GRIN2B 3682/4885OPRK1 829/4885OPRM1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback